| Autor: |
Kato, Shiro, Kishiro, Izumi, Ohnuma, Noboru, Takasaki, Keiji, Okamoto, Shingo, Nakamoto, Takaaki, Kaneko, Noboru, Kumamoto, Hidero |
| Předmět: |
|
| Zdroj: |
Respirology; Mar2000, Vol. 5 Issue 1, p27-32, 6p |
| Abstrakt: |
Objective:In seven patients with systemic sclerosis (SS), we evaluated the clinical effectiveness of oral administration of saprogrelate hydrochloride (SH: 300 mg/day) for 2 months on Raynaud’s phenomenon (RP) and respiratory failure estimated by Hugh-Jones classification. Methodology:We evaluated laboratory data (arterial blood gas (pH, PaO2 and PaCO2), pulmonary function tests (%VC, FEV1/FVC and %DLco), mean pulmonary arterial pressure (mPAP), white blood cell count, C-reactive protein and the plasma levels of fibrinopeptide A (FPA), β-thrombogloblin (β-TG), platelet factor 4 (PF4) and thrombomodulin (TM)) before and after SH administration. Results:The frequency and duration of RP, as well as the coldness, numbness and pain of RP were significantly decreased after SH administration (P < 0.05, P < 0.01 and P < 0.001). Respiratory failure estimated by Hugh-Jones classification was also significantly decreased after SH administration (P < 0.05), and the %DLco was significantly increased (P < 0.01). The mPAP decreased significantly after SH administration (P < 0.05). Plasma FPA, β-TG and PF4 significantly decreased after administration (P < 0.05 and P < 0.01). Conclusions:SH therapy could prevent RP and respiratory failure in patients with SS. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text